Literature DB >> 10421859

Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area.

N M Ampel1.   

Abstract

The prognostic importance of specific and general tests of immune function were examined among a cohort of 170 subjects infected with human immunodeficiency virus type-1 (HIV), living in an area endemic for the fungal infection coccidioidomycosis. Using the proportional hazards model and multivariate analysis, lack of expression of coccidioidal delayed-type hypersensitivity (DTH) was found to be dependent on anergy in response to the non-coccidioidal antigens mumps, Trichophyton and Candida (relative hazard 4.2, 95% CI 1.8-9.8, P=0.001). Among subjects with CD4 lymphocyte counts >/=250 microl-1 on entry into the study, the in vitro lymphocyte transformation (LT) response to the coccidioidal antigen toluene spherule lysate was 4967+/-1652 (mean counts per minute (c.p.m.)+/-SEM) in subjects with coccidioidal DTH compared with 136+/-222 in those with negative DTH (P<0.001). However, amongst those whose CD4 count was <250 microl-1, LT responses were low and there was no significant difference based on coccidioidal DTH (P=0.965). Using the proportional hazards model and multivariate analysis, only a CD4 count <250 microl-1 was prognostically associated with the development of either active coccidioidomycosis or AIDS. These data indicate that immunodeficiency, particularly a CD4 lymphocyte count <250 microl-1, is the most important factor in the lack of expression of specific immunity to coccidioidomycosis and in the development of active coccidioidomycosis among HIV-infected individuals living in the coccidioidal endemic area.

Entities:  

Mesh:

Year:  1999        PMID: 10421859

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  9 in total

Review 1.  Measurement of cellular immunity in human coccidioidomycosis.

Authors:  Neil M Ampel
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

Review 2.  How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.

Authors:  Steven T Denham; Morgan A Wambaugh; Jessica C S Brown
Journal:  J Mol Biol       Date:  2019-05-09       Impact factor: 5.469

Review 3.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  The mannose receptor mediates the cellular immune response in human coccidioidomycosis.

Authors:  Neil M Ampel; Daniel K Nelson; Lijin Li; Sara O Dionne; Douglas F Lake; Keira A Simmons; Demosthenes Pappagianis
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

5.  Spherules derived from Coccidioides posadasii promote human dendritic cell maturation and activation.

Authors:  Sara O Dionne; Abigail B Podany; Yvette W Ruiz; Neil M Ampel; John N Galgiani; Douglas F Lake
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 6.  THE TREATMENT OF COCCIDIOIDOMYCOSIS.

Authors:  Neil M Ampel
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

7.  Concomitant Central Nervous System Toxoplasmosis and Seronegative Disseminated Coccidioidomycosis in a Newly Diagnosed Acquired Immune Deficiency Syndrome Patient.

Authors:  Michael Valdez; Leila Moosavi; Arash Heidari
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

Review 8.  Coccidioidomycosis: A Contemporary Review.

Authors:  Nancy F Crum
Journal:  Infect Dis Ther       Date:  2022-03-01

9.  Infected Aneurysm of the Native Aorta due to Coccidioides posadasii.

Authors:  Jeffrey Huang; Edison J Cano; Fnu Shweta; Aditya S Shah; Audrey N Schuetz; Melanie Bois; Pooja R Gurram
Journal:  Open Forum Infect Dis       Date:  2021-05-23       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.